They concluded that a TRPV1 antagonist rather than a TRPA1 antagonist may ameliorate allergic conjunctivitis by suppressing the Type 2 helper T cell cytokine response in draining lymph nodes [108]. The gene discussed is TRPA1; the disease is atopic conjunctivitis.